Connect with us

Media OutReach

Johnson & Johnson launches The 3rd Opinion in Asia Pacific: a new term to elevate the patient voice in the lung cancer treatment journey

Published

on

  • Newly published research shows up to 77% of patients in Asia Pacific trust and rely on their physicians to decide their treatment for them despite 69% of physicians encouraging patients to engage in shared decision making1.
  • A new term, coined The 3rd Opinion, is designed to spark a social movement that empowers patients to recognize their vital role in shared decision-making, in a region that is disproportionately impacted by lung cancer2.

SINGAPORE –

According to newly published data on NSCLC patient preferences in Future Oncology, up to 77% of patients in Asia Pacific trust and rely on their physicians to decide their treatment for them despite 69% of physicians encouraging patients to engage in shared decision making[1]. Cultural norms around stigma, not questioning authority, and limited understanding of the disease can often be major barriers causing patients not to voice concerns or ask questions, even when healthcare professionals actively encourage their input.

“Being diagnosed with lung cancer is overwhelming. It’s natural for patients to seek clarity, often by pursuing a second opinion, to better understand their condition and treatment options. However, patients often hesitate to express their concerns and treatment goals, causing them to be overlooked in the decision-making process. By creating space for the patient’s own opinion, The 3rd Opinion, creates a new way of thinking about lung cancer treatment and empowers patients to find their voice,” said Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific.

J&J IM Key Visual Reunion The 3rd Opinion

Lung cancer has the highest incidence and mortality rate of all cancers worldwide, with more than 2.5 million people diagnosed every year, and Asia makes up 63% of all patients[2]. Up to 85% of lung cancers are non-small cell lung cancer (NSCLC) and Asians are more prone to certain genetic mutations than the rest of the world. One of the most prevalent is a mutation known as EGFR where 30-40% of all NSCLC diagnoses are in Asia, compared to 10-15% in the United States and Europe[3][4][5]. Often being diagnosed at a late stage, less than 20% of people with these genetic mutations survive beyond five years[6], and up to 40% never get the chance to receive a subsequent therapy after first-line treatment.[7][8][9]

“With the disproportionately high prevalence of certain NSCLC mutations in Asia Pacific, we need to think differently about how we treat patients and what more we can achieve with the first treatment. Treatment options have become increasingly complex and clinical decision making should comprehensively consider disease characteristics, patient treatment goals and values, and aim for an individualized balance between survival, longer lasting disease control and side effects. When shared decision making includes all available options, the final decision can be made collaboratively,” said Prof James Chih-Hsin Yang, Director of National Taiwan University Cancer Center and key advocate for The 3rd Opinion initiative.

J&J IM Key Visual Wedding The 3rd Opinion

Mark Brooke, Chief Executive Officer of Lung Foundation Australia, co-author of the Future Oncology publication and an advocate of The 3rd Opinion agreed, “The physician and patient dynamic is one of trust, but we cannot rely on that alone. The consequence is a potential disconnect between the patient and their healthcare professional around treatment preferences and personal goals. For patients, they often want more time above all else – to witness life’s milestones, more moments with loved ones, and more opportunities to simply live. Patients need to be equipped with adequate disease and treatment information, so they can communicate what matters most to them”.

J&J IM Key Visual Grandchild The 3rd Opinion

The 3rd Opinion will be launched across multiple markets with educational resources, including a Lung Cancer Book of Answers in China, a patient empowerment video and various shared decision making tools across Asia Pacific to spark a social movement that encourages patients to confidently articulate their personal goals for treatment. The creation of a neologism, like The 3rd Opinion, ensures shared decision making becomes accepted into clinical practice and in turn fosters an environment where the doctor’s expertise and the patient goals come together to design the best treatment plan.


[1] Chee Khoon Lee et al. Navigating advanced lung cancer care, patient–physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians. DOI: 10.1080/14796694.2025.2499511

[2] Natia Jokhadze MD, Arunangshu Das MBBS, Don S. Dizon MD. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Volume 74Issue 3CA: A Cancer Journal for Clinicians pages: 224-226 First Published online: April 4, 2024

[3] Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. Journal of Clinical Oncology. 2011; 29(15): 2121-2127.

[4] Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. Journal of Clinical Oncology. 2013; 66(2): 79-89.

[5] Korpanty G, et al. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Frontiers in Oncology. 2014; 4: 204.

[6] Bazhenova L, Minchom A, Viteri S, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021;162:154-161.​

[7] Nieva J, Karia PS, Okhuoya P, et al. A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer [ESMO abstract 1344P]. Ann Oncol. 2023;34(suppl 2):S774 ​

[8] Lee JY, Mai V, Garcia M, et al. Treatment patterns and outcomes of first-line osimertinib-treated advanced EGFR mutated NSCLC patients: a real-world study [IASLC abstract EP08.02-082]. Presented at: IASLC 2022 World Lung Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria.​

[9] Girard N, Leighl NB, Ohe Y, et al. Mortality among EGFR-mutated advanced NSCLC patients after starting frontline osimertinib treatment: a real-world, US attrition analysis. Presented at: the European Lung Cancer Congress; March 29-April 1, 2023; Copenhagen, Denmark. Poster 19P.​

Hashtag: #Johnson&Johnson

The issuer is solely responsible for the content of this announcement.

About The 3rd Opinion

“The 3rd Opinion”, the patients own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.

About Non-Small Cell Lung Cancer

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[10], [11] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[12] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[13] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[14], [15],[16],[17],[18],[19] EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[20] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent. [21], [22] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[23] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[24]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[25].


[10]The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[11] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[12] Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.

[13] Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[14] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[15] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[16] Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 37:97-104.

[17] Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[18] Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.

[19] Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.

[20] American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed March 2025.

[21] Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.

[22] Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65

[23] Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb; 12(2):220-9.

[24] Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[25] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, 2024.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at or at . Follow us at .

Media OutReach

No Judgement, No Awkwardness: More Hongkongers Are Opening Up to AI for Mental Health Support

Published

on

HONG KONG SAR – Media OutReach Newswire – 24 April 2026 – There is a particular kind of exhaustion that comes not from the stress itself, but from carrying it in silence — unsure whether it is serious enough to mention, or whether anyone would truly understand.

A newly completed Hong Kong study suggests there may finally be a way to bridge that gap. The AIM Greater China Psychology Research Group has completed a Hong Kong-based study conducted in the 2025–2026 academic year, comparing the effectiveness of human hypnotherapists against AI in delivering hypnotic experience-based stress relief experiences. The findings were striking: a significant proportion of participants felt that both approaches yielded virtually equivalent levels of relaxation — and more than 60% reported preferring their AI session after the fact.

Over 400 Applicants: A Reflection of a Generation in Need of Being Heard

The research team recruited participants experiencing family-related stress via Facebook. Within a short period of the post going live, over 400 individuals voluntarily applied — a figure that speaks not only to the pervasiveness of stress in modern life, but also to a growing willingness among the public to prioritise their own emotional wellbeing and actively seek self-care solutions.

From the applicant pool, 48 participants were randomly selected to take part. Each participant underwent two separate hypnotic experience stress relief audio sessions, each lasting approximately one hour — one recorded by a human hypnotherapist, and one fully generated by AI, including both the script and voice. Participants then compared their personal experiences of both sessions.

What Humans Can Do, AI Can Do Too

In the most critical area of comparison — stress relief effectiveness — the largest single group of participants (41.7%) rated the AI and human sessions as equally effective. On a scoring basis, the AI hypnotic experience averaged approximately 2.92 points, compared to 2.58 points for the human session — with AI coming out marginally ahead.

The study further found that nearly 90% of participants indicated they would enjoy a session if it genuinely helped them feel relaxed. In other words, what people truly care about is whether it works — not whether the voice behind it belongs to a human or a machine. On this front, AI has passed the test.

Over 60% More Willing to Share Their Feelings with AI

The results around personal preference were perhaps the most eye-opening. When asked which session they enjoyed more, 62.5% of participants chose the AI experience — and among women, that number climbed even higher, to 68.4%.

So what made AI the preferred choice? Researchers believe it comes down to one simple thing: feeling safe. With AI, there is no worry about being judged. No fear of saying the wrong thing. No awkwardness. About 1 in 4 participants said they actually found it easier to talk openly with AI — because it communicates in a way that feels clear, calm, and natural, much like everyday conversation.

The truth is, some things are just easier to say when no one is watching. That is not a flaw in human nature — it is simply how many of us work.

When it came to privacy, the findings were equally reassuring. More than half of all participants said they had no concerns about AI handling their personal information. Only a very small number — just 2.08% — said they felt uncomfortable. This points to a growing sense of trust in AI tools among the general public.

AI Reads the Data; Therapists Read the Person

Beyond the hypnotic experience itself, the local research team also evaluated AI’s capability as an analytical tool — with equally impressive results.

AI was able to rapidly process large volumes of participant responses, objectively assess individual stress levels, and identify underlying patterns. For instance, AI identified that 35% of participants independently expressed a desire for “personal space” or “better soundproofing” in their homes. On the surface, these may seem like trivial lifestyle concerns — yet AI connected this pattern to the reality of Hong Kong residents living in constrained spaces, highlighting a deeper psychological sense of having “nowhere to breathe”. This level of insight would be difficult to uncover through manual review of dozens of questionnaires alone.

AI also observed that many participants habitually occupied the role of “problem-solver” or “mediator” within their households, suppressing their own emotional needs in the process. Researchers noted that this reflects a widely recognised social phenomenon — the pressures faced by eldest daughters and the so-called “sandwich generation,” caught between the responsibilities of caring for ageing parents and raising children. AI’s ability to rapidly identify these hidden emotional burdens allows therapists to bypass lengthy preliminary assessments and focus more swiftly on the core issues that require their attention.

AI Is Here to Help, Not to Take Over

The local research team emphasises that the study was never intended to position AI as a replacement for human therapists. Rather, the aim is to explore how the two can work in tandem. Much like how blood test reports assist physicians in diagnosis, AI can play an analogous supporting role in the mental health field — organising data, identifying patterns, and lowering barriers to seeking help, so that mental health professionals can direct their energy towards the moments that truly require a human touch.

Those who proactively seek psychological support remain a minority, often deterred by the fear of inconvenience, social stigma, or the awkwardness of speaking up. If AI can serve as the bridge that encourages more people to take that first step, that alone may be its most meaningful contribution to society.

Hashtag: #HypnosisInstitute

The issuer is solely responsible for the content of this announcement.

About Hypnosis Institute

Hypnosis Institute is dedicated to helping people in Hong Kong lead healthier and more fulfilling lives through hypnotic experience. We offer accessible and practical hypnotic experience training programmes designed to integrate hypnotic techniques into everyday life, with a focus on stress management, emotional wellbeing, and personal growth.

Hypnosis Institute is Hong Kong’s only hypnotic experience professional development platform that simultaneously operates a research group, social innovation group, practical training group, crisis psychological support group, charitable initiatives, networking events, therapeutic services, and a comprehensive training pathway.

As the sole Hong Kong chapter of the Association for Integrative Medicine (AIM) in the United States, the sole overseas Hong Kong academy of UK educational institution Study House (Quality Licence Scheme), and the sole specialist hypnotic experience training school in Hong Kong under Cambridge International College in the United Kingdom, Hypnosis Institute provides internationally recognised qualifications that contribute to the advancement of the industry.

Founder Charles Leung is a trainer of trainers in the field of hypnotic experience, and has been specially appointed by the Association for Integrative Medicine as the Chief Instructor for Specialist hypnotic experience in Greater China. He has trained over 1,000 hypnotherapists and instructors, upholding the highest standards of professional development in the mental health field.

The Institute’s programmes integrate a comprehensive range of methodologies, including hypnotic experience combined with MBTI personality profiling, DISC behavioural analysis, mental health coaching, emotional education, and the HiddenMe Cards inner child tool — providing a holistic and personalised approach to hypnotic experience practice. Instructors specialise in paediatric hypnotic experience, Internal Family Systems (including inner child) hypnotic experience, stress and insomnia relief hypnotic experience, interpersonal relationship hypnotic experience, as well as hypnotic experience in reminiscence and palliative care.

Driven by the belief that everyone can harness the power of hypnotic experience to enhance their mental wellbeing, Hypnosis Institute is committed to sharing psychological knowledge and providing professional support in the areas of emotional management, life challenges, and the professional development of the hypnotic experience industry.

Follow us at , , and for the latest updates.

Continue Reading

Media OutReach

Reimagining Capital: Inside BizPal Day 2026 and the Launch of CapitalOS

Published

on

JOHOR, MALAYSIA – Media OutReach Newswire – 24 April 2026 – BizPal Malaysia hosted BizPal Day 2026, an invite-only event bringing together investors, SME founders, and ecosystem partners in Johor, where the company formally introduced CapitalOS, its corporate finance platform, and signed Memoranda of Understanding (MOUs) with Malaysian partners My Education Platform and VA Partners.

Attendees of BizPal Day 2026 gather in Johor, Malaysia, bringing together investors, SME founders, and ecosystem partners for the official introduction of CapitalOS, BizPal’s corporate finance platform.

Held at deMori @ FCC Signature, the event featured a live platform demonstration, partner showcase, and networking sessions aimed at facilitating engagement between founders, advisors, and investors.

Introducing CapitalOS

CapitalOS, BizPal’s corporate finance platform, was presented through a live demonstration during the event. The system integrates operational, brand, and financial data into a structured framework designed to support investor readiness and due diligence.

According to BizPal, the platform is intended to help SMEs organise their business information into formats aligned with investor expectations, enabling clearer communication during fundraising discussions.

“SMEs should never walk into a funding conversation unsure of their numbers,” said Ms. Anya Tan, CEO of BizPal Malaysia.

MOUs Expand Distribution Network

The event also included the signing of Memoranda of Understanding between BizPal and two Malaysian partners, My Education Platform and VA Partners. Both organisations will serve as authorised distributors of BizPal’s education and advisory programmes across Malaysia.

Representatives from BizPal and My Education Platform formalise their collaboration through a Memorandum of Understanding (MOU), expanding BizPal’s distribution network across Malaysia.
Representatives from BizPal and My Education Platform formalise their collaboration through a Memorandum of Understanding (MOU), expanding BizPal’s distribution network across Malaysia.

The partnerships expand BizPal’s reach within the SME ecosystem by working with local organisations that support business development and capability building.

“Partnering with BizPal allows us to introduce structured, investor-ready methodologies to the SME community we serve,” said Mr. Jeff Lee, Director, My Education Platform.

A representative from VA Partners is expected to provide a statement following final endorsement.

Global Mentorship Exchange (GMX)

During the event, BizPal also presented the Global Mentorship Exchange (GMX), an ecosystem initiative designed to connect experienced business leaders with high-potential entrepreneurs.

The initiative provides a structured environment for mentorship supported by data-based evaluation and standardised assessment criteria aligned with investor expectations. GMX was first introduced during BizPal’s Data Fundraising Masterclass in December 2025 and was presented to a broader network of partners and investors at BizPal Day.

Next Steps

Following the event, BizPal plans to expand the adoption of CapitalOS and continue developing its partner network across Malaysia and the ASEAN region.
Hashtag: #NoDataNoTalk #DataFundraising #InvestorReady #CapitalReadiness #FinTech #BusinessValuation #ASEANSMEs #BizPalDay


The issuer is solely responsible for the content of this announcement.

About BizPal

BizPal provides data-driven corporate finance solutions designed to help ASEAN SMEs become investor-ready. Its platform, CapitalOS, integrates operational, strategic, and financial data into a unified system that supports business evaluation and investor engagement.

Continue Reading

Media OutReach

Vinhomes Green Paradise Can Gio And IHG Hotels & Resorts Partner To Bring Four International Hotel Brands To The Coastal Mega Urban Development

Published

on

HANOI, VIETNAM – Media OutReach Newswire – 23 April 2026 – Cangio Tourist City Corporation, the developer of Vinhomes Green Paradise, and IHG Hotels & Resorts, one of the world’s leading hotel companies, have signed a strategic partnership agreement to introduce IHG’s hotel brands to Vinhomes Green Paradise Can Gio in Ho Chi Minh City. The collaboration will not only enhance the project’s service ecosystem to international standards, but also lay the foundation for a leading coastal mega urban development, reinforcing Vinhomes Green Paradise Can Gio’s position on the global tourism and resort map.

Under the agreement, IHG will develop four hotels with a total of more than 1,000 rooms at Vinhomes Green Paradise Can Gio, including InterContinental Saigon Can Gio with 400 rooms, Crowne Plaza Saigon Can Gio with 400 rooms, Holiday Inn Express Saigon Can Gio with 130 rooms, and Garner Saigon Can Gio with 130 rooms.

InterContinental Saigon Can Gio, a world-renowned luxury brand, will deliver premium hospitality experiences tailored to international travelers and domestic guests seeking high-end accommodation. Crowne Plaza Saigon Can Gio, one of the largest upscale hotel brands globally, will cater to frequent travelers with modern, flexible spaces designed to optimize productivity and foster connections.

Holiday Inn Express Saigon Can Gio and Garner Saigon Can Gio will expand the destination’s accommodation offering with efficient, high-quality stays focused on value, making the development more accessible to a broader range of guests. This also marks the official debut of both brands in the Vietnamese market.

According to the development timeline, Holiday Inn Express Saigon Can Gio and Garner Saigon Can Gio are expected to open in 2028, followed by InterContinental Saigon Can Gio and Crowne Plaza Saigon Can Gio in 2030.

In this partnership, Vinpearl, a member of Vingroup, will act as the project operator and lead the collaboration with IHG Hotels & Resorts, while coordinating with all stakeholders throughout the development and operational phases.

Together with Vinpearl’s world-class hospitality brand, the addition of four premium IHG hotels will help realize a 7,000-room accommodation ecosystem at Vinhomes Green Paradise Can Gio, meeting the growing demand for extended stays and diverse experiences year-round in Can Gio and Ho Chi Minh City.

Complementing the hospitality offering, a series of large-scale entertainment and resort facilities unique to Vinhomes Green Paradise Can Gio will further elevate the destination. These include the 122-hectare VinWonders theme park featuring the world’s tallest artificial snow mountain and nearly 200 attractions, the 5,000-seat Blue Waves Theater, the 800-hectare Paradise Lagoon, the five-star international cruise port Landmark Harbour, and two 18-hole international-standard golf courses. Together, these developments aim to position Can Gio as a globally-recognized tourism and resort hub, targeting 40 million visitors annually and standing alongside leading destinations in Vietnam and worldwide.

Mr. Rajit Sukumaran, Senior Vice President and Managing Director, East Asia & Pacific, IHG Hotels & Resorts, said: “This agreement marks the beginning of a strategic partnership between IHG and Vingroup. Bringing four of our standout brands to Vinhomes Green Paradise Can Gio reflects the diversity of our portfolio, as well as our strong commitment to supporting Vietnam’s goal of becoming a leading global tourism destination. With brands spanning multiple segments, we believe this collaboration will help create an integrated hospitality ecosystem that meets the diverse needs of travelers at one of Vietnam’s most significant developments.”

Ms. Ngo Thi Huong, Chief Executive Officer of Vinpearl Joint Stock Company, said: “We selected IHG not only for its global brand portfolio but also for its proven operational expertise across international markets. Introducing InterContinental, Crowne Plaza, Holiday Inn Express, and Garner to Vinhomes Green Paradise Can Gio is a key step in completing our service structure and establishing international operating standards for the mega project’s hotel system. With this partnership as a foundation, we believe Vinhomes Green Paradise will progressively emerge as a world-class destination, where a fully integrated ecosystem continues to enhance its appeal to residents and both domestic and international visitors.”

Vinhomes Green Paradise is located in the southeastern part of Ho Chi Minh City. Construction began on April 19, 2025, with a total area of 2,870 hectares. The development features three sides facing the sea and is adjacent to the Can Gio Mangrove Biosphere Reserve, a UNESCO-recognized site. The project is being developed to leading ESG++ standards, integrating green, smart, ecological, and regenerative principles.

The development benefits from a well-connected transport infrastructure network, including the Ben Thanh – Can Gio high-speed railway, which will reduce travel time from central Ho Chi Minh City to just 13 minutes, the Can Gio Bridge, the interchange connecting Rung Sac Road with the Ben Luc – Long Thanh Expressway, and the Can Gio – Vung Tau sea-crossing route, enabling travel between two major tourism hubs in just 10 minutes.

With a diverse range of accommodation options, internationally-standardized hotel systems, and a wide array of cultural, artistic, sports, and entertainment facilities aligned with green, smart, and community-friendly principles, Vinhomes Green Paradise Can Gio stands out as a rare mega urban development that both sets new benchmarks for ESG living and delivers a world-class tourism and resort experience.

Hashtag: #Vinhomes

The issuer is solely responsible for the content of this announcement.

About IHG Hotels & Resorts:

IHG Hotels & Resorts is a global hospitality company with a portfolio of 21 brands and IHG One Rewards, one of the world’s largest hotel loyalty programs with over 160 million members. IHG currently franchises, leases, manages, or owns more than 6,900 hotels across over 100 countries, with more than 2,300 hotels in its development pipeline.

IHG’s brand portfolio spans Luxury & Lifestyle, Premium, Essentials, and Suites segments, including well-known brands such as Six Senses, Regent, InterContinental, Crowne Plaza, Holiday Inn Express, Garner, Staybridge Suites, and Candlewood Suites.

About Vinhomes
Vinhomes is Vietnam’s leading real estate developer, pioneering the development of large-scale, well-planned urban areas with integrated amenities, green living environments, and modern lifestyles. In addition to 36 urban developments currently in operation nationwide, Vinhomes continues to focus on building next-generation mega and super urban developments of regional scale and significance, aspiring to create some of the most livable cities in the world while significantly transforming Vietnam’s urban landscape.

For more information, please visit

Continue Reading

Trending